

Technology Appraisal Committee Meeting (Committee D)

Minutes: **Confirmed**

Date and Time: Wednesday 26 April 2017, 10.00 – 14:15

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present:	1. Professor Gary McVeigh (Chair) 2. Dr Lindsay Smith (Vice Chair) 3. Dr Aomesh Bhatt 4. Professor David Bowen 5. Dr Matthew Bradley 6. Dr Ian Davidson 7. Professor Simon Dixon 8. Professor Rachel Elliott 9. Mrs Gillian Ells 10. Dr Rebecca Harmston 11. Dr Peter Hall 12. Sumithra Maheswaran 13. Dr David Meads 14. Pam Rees 15. Mr William Turner	Present for all notes Present for all notes
-----------------	--	---

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Professor Peter Clark	CDF Clinical Lead, NHS England	Present for all notes
Dr Keith Cooper	Southampton Health Technology Assessments Centre	Present for notes 1 to 12
Ross Dent	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Jenna Dilkes	Project Manager, National Institute for Health and Care	Present for all notes

	Excellence	
Dr Geoff Frampton	Southampton Health Technology Assessments Centre	Present for notes 1 to 12
Dr Syed Hussain	Clinical Expert, nominated by Roche Products, British Uro-Oncology Group (BUG), Royal College of Physicians	Present for notes 1 to 12
Allen Knight	Patient Expert, nominated by Action Bladder UK	Present for notes 1 to 12
Helen Knight	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Teri Morgan	Patient expert, nominated by Fight Bladder Cancer	Present for notes 1 to 12
Professor Thomas Powles	Clinical expert, nominated by Roche Products	Present for notes 1 to 9
Mandy Tonkinson	Administrator, National Institute for Health and Care Excellence	Present for all notes
Ian Watson	Technical Adviser, National Institute for Health and Care Excellence	Present for all notes

Non-public observers:

Karyo Angeloudis	Analyst, PASUL National Institute for Health and Care Excellence	Present for all notes
Steve Estevao	Analyst, PASUL National Institute for Health and Care Excellence	Present for all notes
Ann Greenwood	Senior Medical Editor, National Institute for	Present for all notes

Health and Care Excellence		
Hayley Sharp	Senior Medical Editor, National Institute for Health and Care Excellence	Present for all notes
Lydia Shears	Public Involvement Adviser, National Institute for Health and Care Excellence	Present for all notes
David Thompson	NHS England	Present for all notes
Maroulla Whitely	Business Analyst, National Institute for Health and Care Excellence	Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.
2. Apologies were received from Susan Dutton, Professor Paula Ghaneh, Malcolm Oswald, Professor Femi Oyebode and Dr Paula Parvulescu.

Any other Business

3. None

Appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy [ID939]

Part 1 – Open session

4. The Chair welcomed the invited experts, Dr Keith Cooper, Dr Geoff Frampton, Dr Syed Hussain, Allen Knight, Teri Morgan and Professor Thomas Powles to the meeting and they introduced themselves to the Committee.
5. The Chair welcomed company representatives from Roche Products to the meeting.
6. The Chair asked all Committee members to declare any relevant interests
 - 6.1. Dr Lindsay Smith, Dr Aomesh Bhatt, Professor David Bowen, Dr Matthew Bradley, Dr Ian Davidson, Professor Simon Dixon, Professor Rachel Elliott, Mrs Gillian Ells, Rebecca Harmston, Sumithra Maheswaran, Dr David Meads and Pam Rees all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial

interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

- 6.2. Professor Simon Dixon declared a non-specific non-personal financial interest as he is the Director of a Health Economics Unit that has undertaken work for comparator companies.
 - 6.2.1 It was agreed that this declaration would not prevent Professor Simon Dixon from participating in this section of the meeting.
- 6.3. Williams Turner declared a non-specific personal financial interest as his wife holds shares in Worldwide Healthcare Trust PLC.
 - 6.3.1 It was agreed that this declaration would prevent William Turner from participating in this section of the meeting.
- 6.4. Dr Peter Hall declared a non-specific non-personal financial interest as the University of Edinburgh has received fees from Roche for his participation in an advisory board
 - 6.4.1 It was agreed that this declaration would not prevent Dr Peter Hall from participating in this section of the meeting.

7. The Chair asked all NICE Staff to declare any relevant interests.

- 7.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.

8. The Chair asked all other invited guests to declare their relevant interests.

- 8.1. Dr Keith Cooper, Dr Geoff Frampton and Teri Morgan all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.
- 8.2. Allen Knight declared a non-specific personal non-personal financial interest as Action for Bladder Cancer had received funding from the pharmaceutical industry.
 - 8.2.1. It was agreed that this declaration would not prevent Allen Knight from participating in this section of the meeting.
- 8.3. Professor Syed Hussain declared a non-specific personal financial interest as he had received funding for attending advisory boards from the company and comparator companies.
 - 8.3.1. It was agreed that this declaration would not prevent Professor Syed Hussain from participating in this section of the meeting.

- 8.4. Professor Thomas Powles declared a non-specific personal financial interest as he had received funding when acting in an advisory capacity for the company and comparator companies.
 - 8.4.1. It was agreed that this declaration would not prevent Professor Thomas Powles from participating in this section of the meeting.
9. The Chair introduced the lead team, Rebecca Harmston, Sumithra Maheswaran and Dr David Mead who gave presentations on the clinical effectiveness and cost effectiveness of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.
10. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
11. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
12. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

13. The Committee continued to discuss the clinical and cost effectiveness of atezolizumab for treating metastatic urothelial bladder cancer after platinum-based chemotherapy.
 - 13.1. The committee decision was based on consensus.
14. The Committee instructed the technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting

15. Wednesday 31 May 2017, from 10am -5pm at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.